Eltrombopag Olamine in Increasing Platelet Counts in Patients Undergoing Transplant
Status:
Active, not recruiting
Trial end date:
2022-10-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well eltrombopag olamine works in increasing platelet counts
in patients undergoing transplant. Eltrombopag olamine may help platelet counts and the
immune system recover from blood or bone marrow transplant.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
National Cancer Institute (NCI) Novartis Pharmaceuticals